Reviva Q1 net loss $3.2M; stock moving from Nasdaq to OTCQB effective May 14

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss $3.2M ($0.46/share) vs $6.4M ($2.61) in Q1 2025; cash $22.2M up from $14.4M.
Completed public equity offering raising $10M gross in March 2026.
Filed provisional patent for new brilaroxazine form to extend exclusivity through 2046; FDA feedback expected mid-2026.
RECOVER-2 Phase 3 schizophrenia trial enrollment planned for Q3 2026.
Common stock to stop trading on Nasdaq and move to OTCQB on May 14, 2026, under symbol RVPH.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported first quarter ended March 31, 2026 results: net income net loss of approximately $3.2 million, or $0.46 per share, EPS $0.46 per share.

Period: first quarter ended March 31, 2026
Net income: net loss of approximately $3.2 million, or $0.46 per share
EPS: $0.46 per share
Result: reported results

Exact text from the filing

Reviva Reports First Quarter 2026 Financial Results

View on SEC.gov

Browse all earnings releases →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-016760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.